90Y-oxine-ethiodol, a potential radiopharmaceutical for the treatment of liver cancer

Applied Radiation and Isotopes

Volumn 58, Issue 5, 2003, Pages 567-573

  Yu, Junfeng ^a   Häfeli, Urs O ^a   Sands, Mark ^a   Dong, Yonghua ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

111In; 90Y; Ethiodol; Lipiodol; Liver cancer; Oxine; Oxyquinoline; Radiolabeling; Radiopharmaceutical

Indexed keywords

BIOLOGICAL ORGANS; BODY FLUIDS; DRUG PRODUCTS; LIVING SYSTEMS STUDIES; TUMORS;

LIPOPHILIC COMPLEXES; RADIOPHARMACEUTICALS;

RADIOISOTOPES;

ANTINEOPLASTIC AGENT; ETHIODIZED OIL; OXINE ETHIODOL Y 90; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; YTTRIUM 90; 8 QUINOLINOL; INDIUM; YTTRIUM;

ANIMAL EXPERIMENT; ARTICLE; BREMS RADIATION; DRUG STABILITY; DRUG UPTAKE; EXTRACTION; HUMAN; ISOTOPE LABELING; LIVER CANCER; NONHUMAN; PRIORITY JOURNAL; RABBIT; ANGIOGRAPHY; ANIMAL; ANTIBODY SPECIFICITY; BLOOD; CHEMISTRY; HEPATIC ARTERY; INTRAARTERIAL DRUG ADMINISTRATION; LIVER; LIVER TUMOR; METHODOLOGY; SCINTISCANNING; THIN LAYER CHROMATOGRAPHY;

ANGIOGRAPHY; ANIMALS; CHROMATOGRAPHY, THIN LAYER; DRUG STABILITY; ETHIODIZED OIL; HEPATIC ARTERY; INDIUM RADIOISOTOPES; INJECTIONS, INTRA-ARTERIAL; ISOTOPE LABELING; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; ORGAN SPECIFICITY; OXYQUINOLINE; RABBITS; RADIOPHARMACEUTICALS; YTTRIUM RADIOISOTOPES;

EID: 0038148166     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8043(03)00064-2     Document Type: Article

References (28)

1. Aguayo A., Patt Y.Z. Nonsurgical treatment of hepatocellular carcinoma. Semin. Oncol. 28:2001;503-513.
2. Al-Mufti R.A., Pedley R.B., Marshall D.et al. In vitro assessment of lipiodol-targeted radiotherapy for liver and colorectal cancer cell lines. Br. J. Cancer. 79(11-12):1999;1665-1671.
3. Czakis-Sulikowska D., Malinowska A., Kuznik B. Solvent extraction of yttrium(III) by 1-phenyl-3-methyl-4-benzoyl-5-pyrazolone or 8-hydroxyquinoline from water-ethanol solutions. Chem. Anal. (Warsaw). 39:1994;475-482.
4. Graul E.H., Hundeshagen H. Investigations of radio-Yttrium Y-90 metabolism. Int. J. Appl. Radiat. Isot. 5:1959;243-252.
5. 188Re-TDD, for the treatment of liver cancer. Nucl. Med. Biol. 28(2):2001;197-204.
6. Keng G.H., Sundram F.X., Yu S.W.et al. Preliminary experience in radionuclide therapy of hepatocellular carcinoma using hepatic intra-arterial radio-conjugates. Ann. Acad. Med. Singapore. 31:2002;382-386.
7. Lee Y.S., Jeong J.M., Kim Y.J.et al. Synthesis of Re-188 labeled long chain alkyl diaminedithiol for therapy of liver cancer. Nucl. Med. Commun. 23:2002;237-242.
8. Madsen M.T., Park C.H., Thakur M.L. Dosimetry of iodine-131 ethiodol in the treatment of hepatoma. J. Nucl. Med. 29:1988;1038-1044.
9. Park C.H., Suh J.H., Yoo H.S.et al. Evaluation of intrahepatic I-131 Ethiodol on a patient with hepatocellular carcinoma - therapeutic feasibility study. Clin. Nucl. Med. 11:1986;514-517.
10. Park C., Choi S.I., Kim H.et al. Distribution of lipiodol in hepatocellular carcinoma. Liver. 10:1990;72-78.
11. Partensky C., Sassolas G., Henry L.et al. Intra-arterial iodine 131-labeled lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma. Arch. Surg. 135:2000;1298-1300.
12. 131I-labeled- iodized oil in the treatment of hepatocellular carcinoma. Hepatology. 26:1997;1156-1161.
13. Raoul J.L., Boucher E., Kerbrat P. Nonsurgical treatment of hepatocellular carcinoma. Bull. Cancer. 86(6):1999;537-543.
14. Santin A.D., Hermonat P.L., Ravaggi A.et al. Development and therapeutic effect of adoptively transferred T cells primed by tumor lysate-pulsed autologous dendritic cells in a patient with metastatic endometrial cancer. Gynecol. Obstet. Invest. 49:2000;194-203.
15. 111Indium-oxine-labeled leukocytes in the diagnosis of localized infection in patients with neoplastic disease. Cancer. 54:1984;817-824.
16. Schroeder S., Caughran M., Jochelson M.et al. Imaging of lymphoid structures with indium-111-labeled lymphocytes. Invest. Radiol. 18:1983;87-93.
17. Shen S., DeNardo G.L., Yuan A.et al. Planar gamma camera imaging and quantitation of yttrium-90 bremsstrahlung. J. Nucl. Med. 35:1994;1381-1389.
18. Stanbury, J.B., Barnaby, J., Daza, G., et al., 2002. Recommendations for the use of iodized oil, http://icb.usp.br/~lats/STAMBURY.HTM, accessed on September 17.
19. Stansby G., Bhattacharya S., Hilson A.J.W.et al. Case report. localization of lipiodol-redioiodine in hepatic metastases from renal cell carcinoma Br. J. Radiol. 67:1994;822-824.
20. Stevenson A.F.G. Sr-90/Y-90 biokinetics at incorporation determine the radiation burden to bone marrow. Indian J. Exp. Biol. 38:2000;222-224.
21. Sundram F.X., Yu S.W., Jeong J.M.et al. Rhenium-188-TDD-Lipiodol in treatment of inoperable primary hepatocellular carcinoma - a case report. Ann. Acad. Med. Singapore. 30:2001;542-545.
22. Sundram F.X., Jeong J.M., Zanzonico P.B.et al. Trans-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma. An IAEA sponsored multi-centre phase 1 study. World J. Nucl. Med. 1:2002;5-11.
23. Thakur M.L., Lavender J.P., Arnot R.N.et al. Indium-111 labeled autologous leukocytes in man. J. Nucl. Med. 18:1977;1014-1021.
24. Tilak S.P., Salak W.W., Howard J.M. Direct irradiation of lymph nodes with I-131 tagged ethiodol. Ann. Surg. 163(1):1966;67-73.
25. Towu E., Boxer G., Begent R.et al. In-vitro uptake of radioactive lipiodol I-131 and I-125 by hepatoblastoma. implications for targeted radiotherapy Pediatr. Surg. Int. 17(8):2001;609-613.
26. Wang S.J., Lin W.Y., Chen M.N.et al. Biodistribution of Re-188 Lipiodol infused via the hepatic artery of rats with hepatic tumors. Eur. J. Nucl. Med. 23:1996;13-17.
27. Wang S.J., Lin W.Y., Lui W.Y.et al. Hepatic artery injection of yttrium-90-lipiodol. biodistribution in rats with hepatoma J. Nucl. Med. 37:1996;332-335.
28. Yumoto Y., Jinno K., Inatsuki S.et al. Treatment of hepatocellular carcinoma by transcatheter hepatic arterial injection of radioactive iodized oil solution. Cancer Chemother. Pharmacol. 31(Suppl. I):1992;S128-S136.